Lion Street Advisors LLC Has $812,000 Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Lion Street Advisors LLC raised its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 16.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 9,599 shares of the company’s stock after acquiring an additional 1,344 shares during the quarter. Lion Street Advisors LLC’s holdings in Axsome Therapeutics were worth $812,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of AXSM. FMR LLC boosted its position in shares of Axsome Therapeutics by 20.6% in the 3rd quarter. FMR LLC now owns 1,088,087 shares of the company’s stock worth $97,786,000 after purchasing an additional 185,951 shares during the last quarter. Geode Capital Management LLC lifted its stake in Axsome Therapeutics by 2.7% in the third quarter. Geode Capital Management LLC now owns 908,459 shares of the company’s stock valued at $81,659,000 after buying an additional 23,564 shares during the period. Wellington Management Group LLP boosted its holdings in Axsome Therapeutics by 1.1% during the third quarter. Wellington Management Group LLP now owns 742,745 shares of the company’s stock worth $66,750,000 after buying an additional 8,125 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Axsome Therapeutics by 4.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 322,596 shares of the company’s stock worth $28,992,000 after buying an additional 12,778 shares during the period. Finally, Loomis Sayles & Co. L P increased its stake in shares of Axsome Therapeutics by 11.0% in the 3rd quarter. Loomis Sayles & Co. L P now owns 298,586 shares of the company’s stock valued at $26,834,000 after acquiring an additional 29,497 shares during the last quarter. Institutional investors and hedge funds own 81.49% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on AXSM shares. Truist Financial lifted their price objective on shares of Axsome Therapeutics from $180.00 to $190.00 and gave the stock a “buy” rating in a research note on Monday. Cantor Fitzgerald reissued an “overweight” rating and issued a $121.00 price target on shares of Axsome Therapeutics in a report on Thursday, December 12th. William Blair restated an “outperform” rating on shares of Axsome Therapeutics in a research report on Friday, January 24th. HC Wainwright lifted their target price on Axsome Therapeutics from $180.00 to $190.00 and gave the stock a “buy” rating in a report on Friday, January 31st. Finally, Mizuho increased their price target on Axsome Therapeutics from $122.00 to $137.00 and gave the stock an “outperform” rating in a report on Monday. One equities research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat, Axsome Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $134.00.

Axsome Therapeutics Stock Performance

Axsome Therapeutics stock opened at $112.92 on Wednesday. The company has a quick ratio of 2.37, a current ratio of 2.44 and a debt-to-equity ratio of 1.97. Axsome Therapeutics, Inc. has a 1-year low of $64.11 and a 1-year high of $113.33. The company has a fifty day simple moving average of $94.09 and a 200 day simple moving average of $91.27.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($1.34) earnings per share for the quarter, beating the consensus estimate of ($1.38) by $0.04. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. The company had revenue of $104.76 million during the quarter, compared to analysts’ expectations of $98.71 million. During the same quarter last year, the company earned ($1.32) EPS. Sell-side analysts expect that Axsome Therapeutics, Inc. will post -4.72 EPS for the current fiscal year.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.